

J15 Kentucky & Ohio Ad Hoc Open Meeting: Draft or Revised LCD Public Discussion

Meeting Date & Time: September 17, 2026, 2:30 pm ET

Topics:

- DL40431—MoIDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms
- DL40451—MoIDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic Malignancies
- DL40433—MoIDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal Carcinoma

CURTIS MCFADDEN 0:06

Good afternoon, everyone. My name is Curtis McFadden. I am a Senior Provider Relations Representative, specializing in outreach and education. Welcome to our Kentucky and Ohio Ad Hoc Open Meeting. I am your producer for today's presentation and will be managing things behind the scenes.

I will now yield the floor to our Chief Medical Officer, Dr. Vidya, who will be handling today's presentation. Dr. Vidya, the floor is yours.

Vidya Nagamangala 0:34

Thank you, Curtis, and good afternoon everyone, and thank you so much for joining us. I'm Vidya Nagamangala. I'm one of the chief medical officer and we have here Doctor Berman, who's the other chief Medical officer, and we have Jessica Olsen, who's also the policy expert.

Today I'll be presenting to you the three draft LCD mold ex policies that are in the comment period now.

This is our disclaimer slide.

I'm telling you that what information be present is current as of today. Things can change with CMS. That's the slide.

So we have 3 proposed LCD's. The first one is DL 40431. It's a MoIDX policy, as I mentioned before, genome wide molecular methodologies for the detection of copy number alterations and structural variants in hematologic neoplasms. The second one is DL 40451 MoIDX generation sequencing for hematologic malignancies and suspected hematologic malignancies. Third one is DL 40433 MoIDX transcriptional biomarkers for therapeutic decision making in renal carcinoma, as I mentioned before.

The comment period is now open between August 27, 2026 to October 11th, 2026.

You can get all the details on these draft policies as they're posted now on the Medicare coverage database, also called as the MCD.

You can submit your comments by three methods. This is posted on our website as well. You can mail it to CGS administrators. Attention to the chief medical director with the address listed there where you can fax it to the number. Please make sure your fax cover sheet does have draft LCD comment submission mentioned with the name of the draft LCD and attention Chief medical director. You can send it via e-mail as well and that's the preferred method to cmd.inquiry@cgsadmin.com. Again, these requests should be sent with the draft LCD comment submission with the name of the LCD in the subject line, and if the attachment size for these citations are large sets 15 MB, then please send the articles in supporting documents via multiple smaller emails. And if you're having any trouble or difficulty submitting these comment forms, please contact cmd.inquiry@cgsadmin.com and we can work with you on that.

That's all I have for you all today. Thank you so much for joining us.



Curtis, do you have anything to add?

CURTIS MCFADDEN 3:53

Thank you so much for the information that you shared, Doctor Vidya.

Of course, she gave the information to be able to contact us, but if you have any other questions you can ask those questions to that e-mail address, of course.

Is there anything pertinent you can ask in the chat before we disconnect?

Any questions? OK, I don't see anyone typing anything in the questions in the chat.

So with that being said, we're going to say again, thank you for your attendance and your attention. continue to look to the medical review area on the website for the next series of meetings; open meetings and compliance meetings to be a part of those and have a wonderful day.

Vidya Nagamangala 4:55

Thank you, everyone.